NHS Scotland

organization

Last mentioned: Mar 23, 2026

Timeline

  1. Data Review

    Expected first quarterly report on screening uptake and identification rates in Scotland.

  2. Official Rollout

    Scotland officially begins screening all newborns for the rare muscle disease.

  3. Stage 1 Vote

    Scottish Parliament debates and votes on the general principles of the bill.

  4. Final Vote

    MSPs vote at Stage 1, resulting in the bill being rejected and halted.

  5. Scotland Launch

    Scotland officially begins nationwide screening for all newborns.

  6. Data Evaluation

    Expected first review of screening efficacy and treatment referral rates in Scotland.

  7. Committee Evidence

    Health and Social Care Committee concludes months of testimony from medical, legal, and religious experts.

  8. Committee Scrutiny

    The Health, Social Care and Sport Committee begins hearing evidence from medical and legal experts.

  9. Scottish Policy Review

    Scottish health officials evaluate the feasibility of independent implementation.

  10. Bill Introduction

    Liam McArthur MSP formally introduces the Assisted Dying for Terminally Ill Adults (Scotland) Bill.

  11. Bill Introduced

    Liam McArthur MSP formally introduces the Assisted Dying for Terminally Ill Adults (Scotland) Bill.

  12. Clinical Advocacy

    Intense campaigning by rare disease groups for the inclusion of SMA in UK-wide screening.

  13. UK NSC Recommendation

    The UK National Screening Committee begins formal review of SMA for the newborn panel.

  14. Zolgensma UK Approval

    NHS England and Scotland reach deals to fund the world's most expensive gene therapy.

Stories mentioning NHS Scotland 5

pharma Bullish

Scotland Becomes First UK Nation to Launch Newborn SMA Screening Program

Scotland has officially become the first nation in the United Kingdom to implement routine newborn screening for Spinal Muscular Atrophy (SMA). This landmark public health initiative aims to identify the rare genetic condition within days of birth, enabling immediate access to life-saving gene therapies before irreversible muscle wasting occurs.

2 sources